"Concerned" J&J hopes to stop monthly Tylenol recalls

The most recent recall of Children's Tylenol and related products is "a matter of great concern," writes Johnson & Johnson CEO Bill Weldon on a company blog. In a sustained GMP embarrassment, the late April recall marks the fourth such Tylenol action in as many months. It follows the mid-March move of quality VP Veronica Cruz to McNeil from J&J, and it precedes McNeil's hiring of independent quality experts. That's a lot of QC horsepower rolling into May, the fifth month; hopefully it will forestall a fifth Tylenol recall. Blog | Item

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

AstraZeneca has signed a $750 million deal to produce up to 300 million doses of Oxford University's COVID-19 vaccine by year's end.

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot.